Invention Grant
- Patent Title: Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
-
Application No.: US15548186Application Date: 2016-02-15
-
Publication No.: US11857525B2Publication Date: 2024-01-02
- Inventor: Jill Hamilton-Reeves , Jeffrey M. Holzbeierlein , Thomas Yankee
- Applicant: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
- Applicant Address: CH Vevey
- Assignee: Societe des Produits Nestle S.A.
- Current Assignee: Societe des Produits Nestle S.A.
- Current Assignee Address: CH Vevey
- Agency: K&L Gates LLP
- International Application: PCT/EP2016/053156 2016.02.15
- International Announcement: WO2016/128576A 2016.08.18
- Date entered country: 2017-08-02
- Main IPC: A61K31/198
- IPC: A61K31/198 ; A61K31/07 ; A61K31/202 ; A61K31/70 ; A23L33/12 ; A23L33/13 ; A23L33/14 ; A23L33/00 ; A23L33/175 ; A23L33/155 ; A61K9/00 ; A61K31/7088

Abstract:
A specialized immunonutrition supplement can be administered to a surgical patient to reduce post-operative complications by restraining the expansion of myeloid-derived suppressor cells. The supplement includes one or more of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides, preferably all four of these compounds. The supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to a bladder surgery of the patient to a post-operative day that is three to seven days after the bladder surgery. The supplement can be administered to treat or prevent post-operative paralytic ileus in a bladder cancer patient; treat or prevent surgery-induced, inflammation-induced or cancer-induced cachexia; reduce the incidence of chronic infections resulting from expansion of myeloid-derived suppressor cells in a patient; and/or reduce mRNA expression of pro-inflammatory cytokines in a patient.
Public/Granted literature
Information query
IPC分类: